Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ReNeuron raises over £6 million for stem cell research and development

The stem cell specialist ReNeuron said it had successfully raised over £6 million to fund its ongoing research and development programme.  
ReNeuron raises over £6 million for stem cell research and development

The stem cell specialist ReNeuron (LON:RENE) said it had successfully raised over £6 million to fund its ongoing research and development programme.

Shares were placed with new investors at 4 pence each (last night’s close was 3.99 pence), raising £5.4 million, while existing shareholders were able to participate in the open offer portion of the cash call, adding a further £700,000.

Chief executive Michael Hunt said: “We have raised sufficient overall net proceeds to enable us to progress the company's development strategy to key pre-clinical, regulatory and clinical milestones over the coming year across our core therapeutic programmes."

ReNeuron's ReN001 therapy is currently being used to treat disabled stroke patients as part of the ground-breaking PISCES Study being carried out in Scotland.

In all, 12 stroke sufferers will be given varying doses ReN001 as part of this early-stage trial.

ReNeuron said earlier this month that five patients had been treated in the PISCES stroke study - all three in the first dose cohort and two in the second dose cohort.

No cell-related adverse events or adverse immune-related responses have been reported in any of the patients treated to date, it added, with all five patients seeing some measure of improvement in outcomes, it added.

The company said it expects that the remaining high-dose patient cohorts in the PISCES study will have been treated within the next twelve months, leaving it on-track to submit an application to commence a Phase II study with ReN001 next year.

The ReN001 therapy is based around ReNeuron’s lead neural stem cell line, designated CTX by virtue of its origin from the cortex region of the brain. 

The firm’s other stem cell therapies include ReN009, targeted at peripheral arterial disease , and ReN003, its therapy programme focused on diseases of the retina.

PAD is a chronic, debilitating disease that progressively restricts blood flow in the limbs, causing cramping and chronic pain, and in rare cases it can lead to the loss of a limb. 

During the past year, ReNeuron’s collaborators on its ReN009 programme at the Bristol Heart Institute have presentedpositive pre-clinical efficacy data.

It is continuing to collaborate with the Schepens Eye Research Institute at Havard Medical School on its ReN003 programme.

 

Ian_55ae0ddd437b7.jpg
Why Invest In ReNeuron Group Plc? Read More Here

Register here to be notified of future RENE Company articles
View full RENE profile

ReNeuron Group Plc Timeline

Newswire
February 15 2017
Video
October 28 2016
Article
October 28 2016

Related Articles

shutterstock_216375733.jpg
January 24 2017
At the moment, the healthcare firm M Pharma is a work in progress
newspaper with word cancer magnified
January 30 2017
The start of 2017 has seen some good trial results for its skin cancer treatment, as well as a collaboration deal that will accelerate the development of its lung cancer drug
Blood testing
February 13 2017
Identifying cancer cells early is a key part of combatting the disease, and ANGLE's Parsortix device looks to be developing into a key ally.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use